Nathalie Van Den Haute
Nathalie is a managing director at Oaklins KBC Securities in Belgium and leads Oaklins’ life sciences team. She has more than 17 years of corporate finance and investment banking experience, specializing in mergers & acquisitions (both buy- and sell-side), equity capital markets (initial and secondary public offerings and rights issues) and strategic and financial advisory (valuation exercises, finance structurings, market screenings and independent expert reports). With experience in a broad range of industries, recent transactions include the public-to-private M&A transaction of Resilux by Quva, the public-to-private M&A transaction of Sioen by the founding family, the sale of Rima to Teugels and the acquisition of a minority stake in Studio 100 by 3D Investors and Jonelinvest.
Nathalie joined the corporate finance team in 2005 after obtaining a master’s in commercial engineering (magna cum laude) from Solvay Management School (VUB) in 2004 and a master’s in financial management (magna cum laude) from Vlerick Business School in 2005.